Background: Numerous cross-sectional studies have related exposure to neurotropic infectious agents with cognitive dysfunction in older adults, however, the temporal sequence is uncertain.
in this age group, compelling the need to identify risk factors that could be targeted for prevention or treatment. One potential group of targets comprises infectious agents that can cause lifelong infection in the brain. As chances of virus exposure increase with age, with unpredictable recurrences that can cause neuronal injury, it is possible that such infections contribute to the overall cognitive impairment observed in an aging population. Many previous cross-sectional studies in aging adults have indicated an association between decreased cognitive functioning and exposure to neurotropic infectious agents including Herpes Simplex virus type 1 (HSV-1), [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Herpes Simplex virus type 2 (HSV-2), 2 cytomegalovirus (CMV), 10, [13] [14] [15] [16] and Toxoplasma gondii (TOX). 17 Still, the temporal sequence underlying the associations is uncertain, and causal inferences can therefore not be made. There have been few longitudinal studies examining the relationship between exposure to infectious agents and cognitive decline. One study found an association between exposure to CMV and cognitive decline over a 4-year period in cohort of 1204 Latino individuals. 18 Another study documented an association between IgG antibodies to CMV and cognitive decline and to the development of Alzheimer disease (AD) in a cohort of 849 individuals. 19 In these studies, an association was not found between antibodies to HSV-1 and cognitive decline. An association between IgG antibodies to CMV and cognitive decline was also found in a smaller cohort reported by Carbone et al, 20 but antibodies to HSV-1 were not measured in this study. There have been no studies examining cognitive decline and antibodies to HSV-2 or TOX.
In the present study, we investigated samples from the "Monongahela-Youghiogheny Healthy Aging Team" (MYHAT) study, in which a population-based cohort of participants 65 years and older was evaluated annually for 5 years to investigate cognitive change over time. 21, 22 We assessed the contribution of exposure to CMV, HSV-1, HSV-2, or TOX to cognitive dysfunction at study entry and longitudinal cognitive decline, taking into account potential confounding factors.
METHODS

Study Site and Population
MYHAT is an age-stratified random population sample drawn from the publicly available voter registration lists for a small town region of Pennsylvania (USA). These communities were formerly the hub of the now largely inactive steel industry and have remained economically disadvantaged since the collapse of that industry in the 1970s. The population is stable, that is, characterized by low rates of in and out migration (http://www.ncbi.nlm. nih.gov/pubmed/19340894).
Standard Protocol Approvals, Registrations, and Consents
Community outreach, recruitment, and assessment protocols were approved by the University of Pittsburgh IRB for protection of human subjects. All participants provided written informed consent. Recruitment criteria were (a) aged 65 years or older; (b) living within the selected towns; and (c) not already in long-term care institutions. Individuals were ineligible if they (a) were too ill to participate; (b) had severe vision or hearing impairments; or (c) were decisionally incapacitated. We recruited 2036 individuals, screening out at study entry those who exhibited substantial impairment by scoring <21/30 on an age education-corrected Mini-Mental State Evaluation (MMSE), 23 as the project was designed to study mild impairment. The remaining 1982 individuals were representative of older adults in the targeted communities, with mean (SD) age of 77.6 (7.4) years; they were 61.0% female; 94.7% of mixed European descent, and had median educational level of high school graduate (http://www. ncbi.nlm.nih.gov/pubmed/19340894).
Assessment
Cognitive Assessment
At study entry (baseline) and at each annual follow-up wave, the assessment included a neuropsychological battery designed to test general cognitive function (MMSE), 23 as well as the cognitive domains of attention, executive function, learning/memory, language, and visuospatial function. 24 To create a composite score for each domain, we transformed each test score within that domain into a standardized score by centering to its baseline mean value and dividing by its baseline SD, and then calculated the arithmetic mean of all the standardized scores within that domain. These composite scores were examined in the cross-sectional analyses (see the Statistical analysis section), and were used to calculate slope of cognitive decline over time in the longitudinal analyses.
Laboratory Tests
Each participant was asked to provide nonfasting venous blood samples at study entry; some participants provided these specimens 1 year later instead. Banked serum specimens were sent with appropriate material transfer agreement to the Stanley Neurovirology lab, Johns Hopkins University (JHU) where they were assayed for exposure to CMV. Antibodies to HSV-1, HSV-2, and TOX were assayed similarly. We used highly sensitive microplate solid-phase enzyme immunoassays (ELISA) for immunoglobulin G (IgG) antibody detection. 1 Assay kits were obtained from IBL America, Minneapolis, Minnesota (Toxo CMV) and Focus Diagnostics, Cypress, Ca (HSV-1, HSV-2). The assays for HSV-1 and HSV-2 employed purified glycoproteins, whereas the assays for CMV and TOX used whole organisms as the target antigen. Reference samples were placed on every plate to standardize the results. The levels were adjusted, employing the reference standards in each microplate and for each sample, the level of antibody was expressed as the ratio of the sample signal and the mean reference standard on the same microplate. Exposure to an infectious agent was defined by seropositivity, that is, the presence of a level of antibody greater than the cutoff, as provided by the manufacturer.
Statistical Analysis
Each set of antibodies was dichotomized based on the distribution as described above. We examined baseline relationships between seropositivity for each infectious agent and the demographics [age, sex, race (white and nonwhite), APOE*4 carrier status, and education (less than high school and high school or more)] using univariable logistic regression with the corresponding odds ratios ( Supplementary Table S1 , Supplemental Digital Content 1, http://links.lww.com/WAD/A126). Multiple linear regression models adjusting for demographics were fit to access the effect of antibody levels on each cognitive domain composite and MMSE at baseline (Table 1) .
A 2-stage modeling approach was applied to explore the effect of antibody levels on subsequent change in each cognitive domain composite and MMSE. 25 In the first stage, the rate (slope) of change for each subject in each domain was estimated using a linear mixed model; only individuals with available sera were analyzed. The obtained slopes then served as the outcome variable for the next stage, in which we used linear regression to evaluate the association between infectious exposure and temporal change in cognitive functions. Both univariable linear regression and multiple linear regression models adjusting for demographics were fit for seropositivity assayed through antibody levels. After identifying the significant associations between antibody levels and temporal changes in cognitive domains, average changes in these cognitive domains between the exposed group and nonexposed group for specific virus variables were plotted using the estimated fixed effects from the mixed models.
RESULTS
Of the 1982 individuals who underwent the full assessment at study entry, 1022 provided usable serum specimens. The mean age of this subgroup was 77.5 years (SD = 7.5); 60% were women; 4.9% reported African American ancestry; 12.5%, 46.3%, and 41.2% had less than high school, were high school graduates, or obtained more than high school education, respectively. In the sample, 21% were carriers of the APOE*4 allele. Participants who did and did not provide serum specimens did not have statistically significant differences in age (mean, SD: 77.47, 7.49, and 77.84, 7.39 y, respectively), proportion of women (59.6% and 62.6%), proportions self-reported as white (95.6% and 93.8%) and proportions with Z1 APOE*4 alleles (20.8% and 21.1%). The mean (SD) MMSE scores of those with and without serum were 27.06 (2.36) and 26.81 (2.50), respectively. This relatively small difference of <1 MMSE point attained statistical significance, possibly due to the relatively large sample (P = 0.021).
Potential Predictors of Antibody Levels at Study Entry
The thresholds of seropositivity used to classify individuals as "exposed" varied by infectious agent (see the Statistical analysis section). There were 850 individuals who were classified as CMV antibody positive (83.2%) based on a threshold of 2 U; this level was subsequently used to categorize individuals as "exposed" or "not exposed" (see the Statistical analysis section). 1, 8 Employing appropriate cutoff values, the seropositivity rate was 77.7% for HSV-1, 10.4% for HSV-2, and 47.9% for TOX. The association between seropositivity and demographic variables is depicted in Supplementary Table S1 (Supplemental Digital Content 1, http://links.lww.com/WAD/A126). IgG levels for the antibodies to CMV, HSV-1, and TOX were associated with greater age, female sex, and level of education. Only TOX seropositivity was associated with the APOE*4 allele. Although an association with ethnicity was noted with regard to HSV-1 and HSV-2 seropositivity, only 4.9% of the sample reported African American ethnicity and there were no Latinos. Therefore, in subsequent analyses, only the effects of age, sex, and educational level, but not ethnicity were covaried.
Antibody Levels and Cognitive Functions at Study Entry
In unadjusted cross-sectional analyses, exposure to several infectious agents was significantly associated with lower cognitive domain composite scores in all cognitive domains except attention and with lower MMSE scores ( Supplementary Table S2 , Supplemental Digital Content 2, http://links.lww.com/WAD/A127). After adjustment for age, sex, and education, however, significant associations remained only between seropositivity for HSV-2 and all of the measured cognitive domains (Table 1 ; Supplementary  Table S2 , Supplemental Digital Content 2, http://links. lww.com/WAD/A127).
Seropositivity and Temporal Change in Cognitive Functions
The overall distribution of cognitive changes (mean, SD of the slope) for each domain are shown in Supplementary Table S3 (Supplemental Digital Content 3, http:// links.lww.com/WAD/A128). The average slope of 5-year scores was negative for all cognitive domains except for the memory domain, indicating that those cognitive domains and MMSE (but not memory) declined on average. Supplementary Table S4 (Supplemental Digital Content 4, http://links.lww.com/WAD/A129) presents the average (SD) slope of 5-year cognitive scores for each domain by IgG antibody level (seropositive or seronegative) and the significant results are presented graphically in Figure 1 . In general, the cognitive domains and MMSE, declined less rapidly among IgG-negative participants. Different patterns of association between seropositivity and slopes of change in cognitive domains emerged in longitudinal analyses adjusted for age, sex, and education ( Table 2 and Fig. 1 ). CMV seropositivity was significantly associated with differing trajectories of the memory domain (ie, lack of expected practice effect over time) and visuospatial domain (ie, greater decline), whereas HSV-2 exposure was associated with greater decline in the memory domain alone and TOX was associated with more rapid decline in executive function and changes in MMSE scores. HSV-1 seropositivity was not associated with any of the cognitive domains or with MMSE scores.
DISCUSSION
Through repeated assessment of the population-based MYHAT cohort, the temporal trajectory of cognitive changes was assessed in relation to 4 common infectious agents that can cause cerebral infection; we found significant associations with exposure to CMV, HSV-2, and TOX but not with HSV-1. The associations are unlikely to reflect the sequelae or prior encephalitis due to any of these agents, in view of the exclusion criteria applied in the study. The associations were most significant for HSV-2 exposure and temporal decline in the domain of memory. HSV-2 seropositivity was also associated with lower performance on several cognitive domains at baseline, even when controlling for potential confounding variables. These findings are unexpected, given the paucity of previous studies of cognitive consequences of HSV-2 infections. As HSV-2 is largely sexually transmitted, it is also possible that HSV-2 positivity is a marker for other sexually transmitted disorders or sexual behaviors which are themselves associated with cognitive impairments and cognitive decline. HSV-2 can establish latency within the brains of experimental animals 26 and occasionally cause encephalitis in immunecompetent older adults. 27 It is thus possible that HSV-2 can contribute to cognitive impairments in some individuals. Active HSV-2 infections can be treated effectively with available antiviral medications and the rate of HSV-2 transmission can be decreased by the use of antiviral therapy and safe sexual practices. If confirmed, a direct association between HSV-2 infections and cognitive impairment and cognitive decline thus might provide additional modalities for the prevention and treatment of cognitive impairments in some individuals.
In addition to HSV-2, we found a significant association between seropositivity to TOX and a decline in the domain of executive functioning and MMSE scores.
Although TOX infections in immune-competent individuals have been previously considered to be asymptomatic, recent studies have indicated that latent forms of Toxoplasma can be associated with behavioral anxiety disorders 28 and cognitive impairment 29 in some populations. Our findings indicate that serological evidence of exposure to TOX could also be associated with cognitive decline in aging individuals. Additional populations should be assessed in order to document the generalizability of this finding. There are currently no available medications which can effectively treat the tissue cyst form of TOX. 30 However, Toxoplasma transmission can be prevented by a number of public health measures including the freezing and adequate cooking of meat which might contain tissue cysts and the purification of drinking water which might contain oocysts. 31 Our finding of an association between serological evidence of exposure to CMV and cognitive decline confirms and extends the results of 2 prior longitudinal 
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Seropositive Seronegative FIGURE 1. Significantly greater temporal decline in cognitive domains/MMSE scores associated with seropositivity (exposure). Antibody levels were dichotomized using predetermined cutoff values and seropositivity used to indicate infectious exposure. The cognitive domains that showed significantly greater temporal decline among seropositive (exposed) individuals in Table 2 are graphed. The estimated average changes in these cognitive domains between the exposed group and unexposed group for each infection were plotted against annual evaluations using fixed effects of mixed models. CMV indicates cytomegalovirus; HSV-2, Herpes Simplex virus, type 2; MMSE: Mini-Mental State Examination; TOX, Toxoplasma gondii.
analyses. A prospective cohort-based study showed elevated rates of cognitive decline over 4 years among Mexican Americans with elevated CMV antibody levels. 18 Cognitive function was only assessed in that study using the MMSE. In another recent study, CMV seropositivity was associated with an even higher rate of decline when a more comprehensive and sensitive estimate of global cognition was estimated. 19 This study also related CMV exposure to increased risk of AD (relative risk = 2.15). CMV as a putative risk factor for cognitive decline has enormous public health impact because individuals of all ages are prone to infection, starting in the intrauterine period to older US adults for whom seropositivity rates can exceed 90% (http://www.cdc.gov/nchs/nhanes.htm). 13 CMV primarily infects lymphoid tissues and salivary glands, but infection can also occur in the brain. 14 Viral DNA has also been detected in nonencephalitic postmortem brain tissues, suggesting viral spread to the brain during persistent infection. 15 The Institute of Medicine recently published a report on "Cognitive Aging" to draw attention to incremental cognitive dysfunction as we age (http://iom.nationalacademies.org/Reports/2015/Cognitive-Aging.aspx). Our results suggest that a portion of cognitive aging could be attributed to chronic exposure to particular infectious agents. Another possibility is that such infections decrease "brain reserve," making the brain more susceptible to other insults such as cerebrovascular disease. In the case of CMV, there are several plausible mechanisms for the infection-related cognitive decline, whereas others can be discounted. The association could be mediated by exaggerated or altered immunologic responses to the target agent that has been noted in older individuals. 32, 33 Because CMV infection is common in lymphatic tissues, it may alter the immune response to other infectious organisms or inflammation too. 34 Cognitive decline related to direct cytopathic effects of CMV, subclinical reactivation, or CMV-associated cardiovascular dysfunction are plausible. 35 Cognitive decline could also reflect secondary neurotoxic effects of cytokines released peripherally during reactivation or even antigenrelated "immunosenescence." [36] [37] [38] Others have suggested that the links between CMV and other viral infections and the different effects on memory could relate to more generalized immune dysregulation with more direct neuronal damage, such as HSV-1. 11 Further work exploring more specific immune markers, such as interferons and interleukins will be necessary to follow-up this work. Some infectious agents, particularly CMV have been suggested as risk factors for vascular disease, indicating another possible link between infectious agents and cognitive dysfunction. 19 Although a prior study did not find any evidence for such a link, it may be instructive to investigate the role of vascular risk factors. 19 The observed changes are unlikely to reflect a general decline in health, as only certain cognitive domains were affected. As they have been less frequently studied, the possible associations between cognitive impairment and TOX and HSV-2 are less well defined. In the case of TOX, it is of note that the experimental infection of mice can result in cognitive impairment with some variation dependent upon the strain of Toxoplasma and the strain of mice. The mechanisms are not known, but may relate to both direct effect of the parasite on the brain as well as the host response to infection. 39 Additional studies should be directed at possible mechanisms linking TOX exposure to cognitive decline in aging adults. In summary, several mechanisms could explain the associations, including effects specific to each agent, or more general immunologic sequelae of infection.
Contrary to other studies which have demonstrated an increased risk of AD associated with HSV-1 exposure, we did not find any significant association with memory or any cognitive dysfunction. 35 Our findings are consistent with those of Aiello et al 12 and Barnes et al, 19 which also did not find associations between serological exposure to HSV-1 and cognitive decline. The lack of finding of an association between exposure to HSV-1 and cognitive decline does not rule out any role for HSV-1, as the type-specific assays which were used do not have sufficient sensitivity to detect different stages of HSV-1 infection.
Some limitations of our analyses should be noted. CMV, TOX, and HSV-2 exposure rates for ethnic minority communities in the United States are relatively high 40 ; and greater cognitive decline has been reported among CMVexposed African Americans. 19 We could not detect a similar pattern, likely because African Americans formed only 5% of the MYHAT sample. For the same reason, the potential confounding effect of ethnic differences in seroprevalence rates could not be analyzed meaningfully. Socioeconomic status is strongly correlated with exposure to many infectious agents, with poorer individuals experiencing higher infection rates. As educational attainment is the most reliable and accurate measure of socioeconomic status in our sample, we included it as a covariate in our analyses relating infectious agent to cognitive function. As it is difficult to accurately measure many neurotropic infectious agents directly in blood samples, antibody levels were used as proxies for exposure. Although the antibody assays are highly sensitive and specific, it is not possible to estimate the timing or duration of exposure. As we tested associations reported previously and as exposure to infectious agents is correlated, the appropriate level of correction for multiple comparisons is difficult to determine. Despite the relatively large size, the sample did not have sufficient power to examine the interaction of exposures to multiple infectious agents; larger samples should be analyzed. Lifestyle-related factors, host-related immune factors, or other infections can also be associated with temporal changes in cognition. These variables are often correlated, so it can be difficult to tease out their individual effects. In contrast, the different effect sizes noted here for the infectious agents, and their differing temporal trajectories suggest that some effects could be related to individual infectious agents.
In conclusion, our analyses indicate that CMV, HSV-2, or TOX exposure are associated with cognitive decline in older persons, explaining a small but significant proportion of what is generally dismissed as age-related decline. The results are important from a public health perspective, as CMV, HSV-2, and TOX infections are highly prevalent, and several options for prevention and treatment are available. A randomized-controlled trial of suitable pharmacotherapy could also further test the associations; if successful, it would suggest a potential therapeutic option for older adults. An increased understanding of the role of infectious agents may ultimately indicate preventive measures.
